NEW YORK (GenomeWeb News) - Alnylam Pharmaceuticals has amended its two RNAi collaboration agreements with Merck and consolidated them into a single collaboration, Alnylam said today.
The amendments focus on the nine new therapeutic targets that Merck will name at a later date. These new programs are in addition to the existing collaboration on NOGO pathway for spinal cord injury treatments.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.